Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Current Assets (2016 - 2025)

IGC Pharma has reported Current Assets over the past 15 years, most recently at $2.0 million for Q3 2025.

  • Quarterly Current Assets fell 52.85% to $2.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Sep 2025, down 52.85% year-over-year, with the annual reading at $2.9 million for FY2025, 21.84% down from the prior year.
  • Current Assets was $2.0 million for Q3 2025 at IGC Pharma, down from $2.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $23.5 million in Q1 2021 and troughed at $2.0 million in Q3 2025.
  • The 5-year median for Current Assets is $6.1 million (2023), against an average of $9.4 million.
  • Year-over-year, Current Assets surged 68.44% in 2021 and then crashed 61.7% in 2023.
  • A 5-year view of Current Assets shows it stood at $19.2 million in 2021, then crashed by 51.37% to $9.4 million in 2022, then crashed by 61.7% to $3.6 million in 2023, then dropped by 14.85% to $3.1 million in 2024, then plummeted by 34.32% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Current Assets are $2.0 million (Q3 2025), $2.2 million (Q2 2025), and $2.9 million (Q1 2025).